This metric is misleading without regard to the expected growth of each stock and their return on invested capital. In NXT’s case both of these metrics are well above the industry average (and in some cases double).
Refer to the recent research reports by Goldman Sachs, Evans & Partners and Macquarie if you want to substantiate this.
Hope that helps.
- Forums
- ASX - By Stock
- NXT
- re my questions to investor relations
NXT
nextdc limited
Add to My Watchlist
2.82%
!
$14.59

re my questions to investor relations, page-35
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.59 |
Change
0.400(2.82%) |
Mkt cap ! $9.087B |
Open | High | Low | Value | Volume |
$14.66 | $14.82 | $14.57 | $962.8K | 65.63K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 75 | $14.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.59 | 941 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 177 | 14.790 |
6 | 598 | 14.780 |
5 | 299 | 14.770 |
5 | 641 | 14.760 |
3 | 370 | 14.750 |
Price($) | Vol. | No. |
---|---|---|
14.830 | 465 | 3 |
14.840 | 1240 | 3 |
14.850 | 7473 | 3 |
14.860 | 175 | 2 |
14.870 | 1330 | 3 |
Last trade - 10.04am 30/06/2025 (20 minute delay) ? |
Featured News
NXT (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online